WO2000058473A3 - Nucleic acids including open reading frames encoding polypeptides; 'orfx' - Google Patents

Nucleic acids including open reading frames encoding polypeptides; 'orfx' Download PDF

Info

Publication number
WO2000058473A3
WO2000058473A3 PCT/US2000/008621 US0008621W WO0058473A3 WO 2000058473 A3 WO2000058473 A3 WO 2000058473A3 US 0008621 W US0008621 W US 0008621W WO 0058473 A3 WO0058473 A3 WO 0058473A3
Authority
WO
WIPO (PCT)
Prior art keywords
orfx
open reading
reading frames
nucleic acids
frames encoding
Prior art date
Application number
PCT/US2000/008621
Other languages
French (fr)
Other versions
WO2000058473A2 (en
Inventor
Richard A Shimkets
Martin Leach
Original Assignee
Curagen Corp
Richard A Shimkets
Martin Leach
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curagen Corp, Richard A Shimkets, Martin Leach filed Critical Curagen Corp
Priority to CA002383592A priority Critical patent/CA2383592A1/en
Priority to AU37745/00A priority patent/AU3774500A/en
Priority to EP00916677A priority patent/EP1165784A2/en
Priority to JP2000608754A priority patent/JP2004507202A/en
Publication of WO2000058473A2 publication Critical patent/WO2000058473A2/en
Publication of WO2000058473A3 publication Critical patent/WO2000058473A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)

Abstract

The present invention provides open reading frames encoding isolated polypeptides, as well as polynucleotides encoding ORFX and antibodies that immunospecifically bind to ORFX or any derivative, variant, mutant, or fragment of the ORFX polypeptides, polynucleotides or antibodies. The invention additionally provides methods in which the ORFX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.
PCT/US2000/008621 1999-03-31 2000-03-31 Nucleic acids including open reading frames encoding polypeptides; 'orfx' WO2000058473A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002383592A CA2383592A1 (en) 1999-03-31 2000-03-31 2384891 acids including open reading frames encoding polypeptides; orfx
AU37745/00A AU3774500A (en) 1999-03-31 2000-03-31 Nucleic acids including open reading frames encoding polypeptides; "orfx"
EP00916677A EP1165784A2 (en) 1999-03-31 2000-03-31 Nucleic acids including open reading frames encoding polypeptides; "orfx"
JP2000608754A JP2004507202A (en) 1999-03-31 2000-03-31 Nucleic acid containing an open reading frame encoding a polypeptide; "ORFX"

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US12760799P 1999-03-31 1999-03-31
US60/127,607 1999-03-31
US12763699P 1999-04-02 1999-04-02
US60/127,636 1999-04-02
US12772899P 1999-04-05 1999-04-05
US60/127,728 1999-04-05
US54076300A 2000-03-30 2000-03-30
US09/540,763 2000-03-30

Publications (2)

Publication Number Publication Date
WO2000058473A2 WO2000058473A2 (en) 2000-10-05
WO2000058473A3 true WO2000058473A3 (en) 2001-01-25

Family

ID=27494693

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008621 WO2000058473A2 (en) 1999-03-31 2000-03-31 Nucleic acids including open reading frames encoding polypeptides; 'orfx'

Country Status (5)

Country Link
EP (1) EP1165784A2 (en)
JP (1) JP2004507202A (en)
AU (1) AU3774500A (en)
CA (1) CA2383592A1 (en)
WO (1) WO2000058473A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212228B2 (en) 2005-11-24 2015-12-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9512232B2 (en) 2012-05-09 2016-12-06 Ganymed Pharmaceuticals Ag Antibodies against Claudin 18.2 useful in cancer diagnosis

Families Citing this family (258)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6372473B1 (en) 1997-05-28 2002-04-16 Human Genome Sciences, Inc. Tissue plasminogen activator-like protease
US6482932B1 (en) * 1997-11-05 2002-11-19 Ribozyme Pharmaceuticals, Incorporated Nucleoside triphosphates and their incorporation into oligonucleotides
US6617438B1 (en) * 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US6528640B1 (en) * 1997-11-05 2003-03-04 Ribozyme Pharmaceuticals, Incorporated Synthetic ribonucleic acids with RNAse activity
US7033772B1 (en) 1998-01-15 2006-04-25 Millennium Pharmaceuticals, Inc. Methods of identifying inhibitors of fatty acid transport proteins (FATP)
US6300096B1 (en) 1998-01-15 2001-10-09 Whitehead Institute For Biomedical Research Polynucleotides encoding fatty acid transport proteins
US6365365B1 (en) 1998-03-20 2002-04-02 The Regents Of The University Of California Method of determining whether an agent modulates glycosyl sulfotransferase-3
US6265192B1 (en) 1998-03-20 2001-07-24 The Regents Of The University Of California Glycosly sulfortransferase-3
US7125959B2 (en) 1998-05-15 2006-10-24 Genentech, Inc. PRO4405 polypeptides
WO2001066756A2 (en) * 2000-03-07 2001-09-13 Millenium Pharmaceuticals, Inc. 22105, a human thioredoxin family member and uses thereof
EP1593687A3 (en) * 1998-06-10 2006-10-18 Bayer Corporation Human genes differentially expressed in colon cancer
US20030003507A1 (en) 1999-06-02 2003-01-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7258973B2 (en) 1998-08-31 2007-08-21 Mayo Foundation For Medical Education & Research Method for detecting a differentially expressed sequence
US20030096391A1 (en) * 2000-12-22 2003-05-22 Millennium Pharmaceuticals, Inc. 17903, a novel human aminopeptidase and uses therefor
US6730491B2 (en) 2000-02-29 2004-05-04 Millennium Pharmaceuticals, Inc. 2504, 15977, and 14760, novel protein kinase family members and uses therefor
JP4315301B2 (en) * 1998-10-30 2009-08-19 独立行政法人科学技術振興機構 Human H37 protein and cDNA encoding this protein
US7867731B2 (en) 1998-11-04 2011-01-11 Novartis Vaccines And Diagnostics, Inc. HX2004-6 polypeptide expressed in cancerous cells
US6743602B1 (en) 1999-07-26 2004-06-01 Chiron Corporation Polynucleotides differentially expressed in adenocarcinomas, polypeptides encoded thereby, and methods of use thereof
EP1141269A4 (en) * 1998-12-30 2003-03-26 Millennium Pharm Inc Secreted proteins and uses thereof
ATE318303T1 (en) * 1999-02-12 2006-03-15 Genentech Inc GENE AMPLIFIED IN TUMORS AND RELATED MATERIALS AND METHODS
PT1626058E (en) * 1999-03-08 2008-02-15 Genentech Inc Compositions and methods for the diagnosis of tumour
WO2003004623A2 (en) * 2001-03-27 2003-01-16 Human Genome Sciences, Inc. Human secreted proteins
EP1144600B1 (en) * 1999-03-19 2008-07-30 Aventis Pharmaceuticals Inc. Akt-3 nucleic acids, polypeptides, and uses thereof
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
NZ527292A (en) * 1999-03-23 2005-03-24 Genentech Inc Secreted and transmembrane polypeptides PRO1484 and nucleic acids encoding the same, with homology to an adipocyte complement-related protein
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU5173400A (en) * 1999-05-28 2000-12-18 Sugen, Inc. Protein kinases
WO2000075320A2 (en) * 1999-06-07 2000-12-14 Lexicon Genetics Incorporated Human genes and proteins encoded thereby
JP2003529325A (en) * 1999-06-17 2003-10-07 インサイト・ゲノミックス・インコーポレイテッド Human transport protein
DE19928021A1 (en) * 1999-06-18 2000-12-21 Basf Ag New nucleic acid encoding testis-specific calpain-11, useful for identifying specific inhibitors for treatment of fertility disorders
WO2001002586A1 (en) * 1999-06-29 2001-01-11 Mcgill University Human alpha 1,2-mannosidase
CA2383690A1 (en) * 1999-07-23 2001-02-01 Human Genome Sciences, Inc. 29 human secreted proteins
WO2001007614A1 (en) * 1999-07-26 2001-02-01 Chiron Corporation Polynucleotides differentially expressed in adenocarcinomas, polypeptides encoded thereby, and methods of use thereof
DE19936563A1 (en) * 1999-08-04 2001-02-08 Boehringer Ingelheim Int Tumor Associated Antigen
KR100543857B1 (en) * 1999-09-01 2006-01-23 제넨테크, 인크. Promotion or Inhibition of Angiogenesis and Cardiovascularization
US6818750B2 (en) * 1999-09-01 2004-11-16 The Burnham Institute Card proteins involved in cell death regulation
EP1127118A1 (en) * 1999-09-02 2001-08-29 Smithkline Beecham Plc Human gs protein regulator gene
US20020107381A1 (en) * 2000-09-29 2002-08-08 Friddle Carl Johan Novel human proteases and polynucleotides encoding the same
WO2001016336A1 (en) * 1999-09-02 2001-03-08 Lexicon Genetics Incorporated Human calcium dependent proteases and polynucleotides encoding the same
US6329171B1 (en) * 1999-09-30 2001-12-11 Millennium Pharmaceuticals, Inc. 23484, A novel human ubiquitin protease
US20020045212A1 (en) * 2000-02-29 2002-04-18 Glucksmann Maria Alexandra Novel human GTPase activator proteins
US7329529B2 (en) 1999-09-03 2008-02-12 Millennium Pharmaceuticals, Inc. Ubiqutin proteases
AU6974900A (en) * 1999-09-07 2001-04-10 University Health Network A p53-induced protein with a death domain that can promote apoptosis
AU7494200A (en) * 1999-09-15 2001-04-17 Incyte Genomics, Inc. Proteins associated with cell differentiation
AU6976500A (en) 1999-09-16 2001-04-17 Amgen Canada Inc. Nrage nucleic acids and polypeptides and uses thereof
US7029895B2 (en) 1999-09-27 2006-04-18 Millennium Pharmaceuticals, Inc. 27411, a novel human PGP synthase
US6451994B1 (en) 1999-09-27 2002-09-17 Millennium Pharmaceuticals, Inc. 23413, a novel human ubiquitin protease
GB9924060D0 (en) * 1999-10-11 1999-12-15 Chiron Spa VIP54 protein
US20020081625A1 (en) * 1999-10-14 2002-06-27 John Ford Member of the immunoglobulin superfamily and uses thereof
US6420155B1 (en) * 1999-10-14 2002-07-16 Curagen Corporation Aortic carboxypeptidase-like protein and nucleic acids encoding same
JP2003512055A (en) * 1999-10-19 2003-04-02 ザ ウェルカム トラスト リミティド アズ トラスティー トゥ ザ ウェルカム トラスト Human SIT4-associated protein-like (SAPL) proteins and encoding genes; uses thereof
US20020081679A1 (en) * 1999-10-22 2002-06-27 Millennium Pharmaceuticals, Inc. NARC8 programmed cell-death-associated molecules and uses thereof
EP1234042A1 (en) * 1999-10-25 2002-08-28 Millennium Pharmaceuticals, Inc. Protein 27875, a human adam-ts homolog
AU1449001A (en) * 1999-11-05 2001-06-06 Human Genome Sciences, Inc. 28 human secreted proteins
CA2391007A1 (en) * 1999-11-10 2001-05-17 Lexicon Genetics Incorporated Novel human atpase proteins and polynucleotides encoding the same
US7005285B1 (en) 1999-11-15 2006-02-28 Pharmacia & Italia S.P.A. Human p21-activated kinase 5 polypeptide
EP1244793A2 (en) * 1999-11-17 2002-10-02 Curagen Corporation Serine/threonine kinase and serine protease polypeptides and nucleic acids encoding same
EP1250426A2 (en) * 1999-12-01 2002-10-23 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding same
US20030109428A1 (en) 1999-12-01 2003-06-12 John Bertin Novel molecules of the card-related protein family and uses thereof
WO2001040468A2 (en) * 1999-12-01 2001-06-07 Millennium Pharmaceuticals, Inc. Molecules of the card-related protein family and uses thereof
AU2084601A (en) * 1999-12-10 2001-06-18 Biogen, Inc. Novel polypeptides and polynucleotides encoding same
US7115558B2 (en) * 1999-12-16 2006-10-03 Cytochroma Inc. P450RAI-2(P450 Cytochrome 26B), encoding nucleic acid molecules and methods and uses thereof
WO2001046227A2 (en) * 1999-12-21 2001-06-28 University Of Zurich 'dispatched' polypeptides
CA2395102A1 (en) * 1999-12-23 2001-06-28 Incyte Genomics, Inc. Human kinases
CZ20022438A3 (en) * 2000-01-12 2002-10-16 Yale University Nucleic acid encoding Nogo receptor, isolated polypeptide, and pharmaceutical preparation for stimulating growth of axons
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
AU2001230560A1 (en) * 2000-02-01 2001-08-14 Taisho Pharmaceutical Co. Ltd. Novel gene tig104alpha and protein tig104alpha encoded thereby
AU2001233156A1 (en) * 2000-02-01 2001-08-14 Human Genome Sciences, Inc. Bcl-2-like polynucleotides, polypeptides, and antibodies
AU2001238143A1 (en) 2000-02-09 2001-08-20 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Tumor suppressor gene, p47ing3
US7078205B2 (en) 2000-02-17 2006-07-18 Millennium Pharmaceuticals, Inc. Nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, atpase molecules, acyltransferase molecules, pyridoxal-phosphate dependent enzyme molecules and uses therefor
SE0100472L (en) * 2000-02-18 2001-08-19 Hoffmann La Roche New metalloproteases having thrombospondome domains and nucleic acid compositions encoding these
DE10007468A1 (en) * 2000-02-18 2001-08-23 Basf Lynx Bioscience Ag New central nervous protein that modulates K · + · currents
GB0004196D0 (en) * 2000-02-19 2000-04-12 Smithkline Beecham Plc Novel compounds
AU2001243283A1 (en) * 2000-02-25 2001-09-03 Millennium Pharmaceuticals, Inc. 44576, a novel g-protein coupled receptor and uses therefor
US20040033509A1 (en) 2000-07-18 2004-02-19 Millennium Pharmaceuticals, Inc. Novel 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 molecules and uses therefor
US20010039331A1 (en) * 2000-03-31 2001-11-08 Hunter John J. 16836, a novel human phospholipase C family member and uses thereof
AU2001241928A1 (en) * 2000-02-29 2001-09-12 Millennium Pharmaceuticals, Inc. Transferase 32253 and use therefor
US6864078B2 (en) 2000-02-29 2005-03-08 Millennium Pharmaceuticals, Inc. 14790, novel protein kinase molecule and uses therefor
AU6802801A (en) * 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001245354A1 (en) * 2000-03-02 2001-09-12 Human Genome Sciences, Inc. Serine/threonine phosphatase polynucleotides, polypeptides, and antibodies
WO2001064740A1 (en) * 2000-03-02 2001-09-07 Chugai Seiyaku Kabushiki Kaisha Dna encoding squalene epoxidase promoter
US7301016B2 (en) 2000-03-07 2007-11-27 Millennium Pharmaceuticals, Inc. Human transferase family members and uses thereof
WO2001072975A2 (en) * 2000-03-24 2001-10-04 Millennium Pharmaceuticals, Inc. Human methyl transferase family member, 25552, and uses thereof
US20020055159A1 (en) * 2000-06-15 2002-05-09 Meyers Rachel A. 23680,a novel human aminotransferase and uses therefor
AU2001243569A1 (en) * 2000-03-10 2001-09-24 Curagen Corporation Novel polypeptides and nucleic acids encoding same
EP1265920B9 (en) * 2000-03-22 2007-01-24 Curagen Corporation Angiogenesis-associated proteins, and nucleic acids encoding the same
CA2404310A1 (en) 2000-03-24 2001-10-04 Meike Lorenz A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
US7166701B2 (en) * 2000-03-24 2007-01-23 Merck Patent Gmbh Human survivin interacting protein 1 (SIP-1)
JP2001335598A (en) * 2000-03-24 2001-12-04 Takeda Chem Ind Ltd New protein, method for producing the same and use thereof
AU2001247570A1 (en) * 2000-03-24 2001-10-08 Millennium Pharmaceuticals, Inc. 32451, a novel human ubiquitin conjugating enzyme-like molecule and uses thereof
FR2806739B1 (en) * 2000-03-27 2005-02-18 Fond Jean Dausset Ceph GENES INVOLVED IN INFLAMMATORY BOWEL DISEASES AND THEIR USE
EP1138768A3 (en) * 2000-03-27 2002-08-07 Leadd B.V. Apoptin-associating protein AAP-5
EP1138765A1 (en) * 2000-03-27 2001-10-04 Leadd B.V. Apoptin-associating proteins AAP-5 and AAP-6
EP1275717A4 (en) * 2000-03-29 2004-10-06 Kyowa Hakko Kogyo Kk Proliferative glomerular nephritis-associated gene
US20030198953A1 (en) * 2000-03-30 2003-10-23 Spytek Kimberly A. Novel proteins and nucleic acids encoding same
WO2001072957A2 (en) * 2000-03-31 2001-10-04 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
JP2003530111A (en) * 2000-04-07 2003-10-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Human pyruvate dehydrogenase phosphatase
WO2001079272A2 (en) * 2000-04-18 2001-10-25 Tularik Inc. Sitosterolemia susceptibility gene (ssg): compositions and methods of use
US20020019348A1 (en) * 2000-08-02 2002-02-14 Applera Corporation Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU2001253804A1 (en) * 2000-04-26 2001-11-07 Pe Corporation (Ny) Isolated human transporter proteins, nucleic acid molecules encoding the same, and uses thereof
CA2407435A1 (en) * 2000-04-28 2001-11-08 Incyte Genomics, Inc. Rna metabolism proteins
EP1282706A2 (en) * 2000-05-02 2003-02-12 MERCK PATENT GmbH Natrium-calcium exchanger protein
US6808876B1 (en) * 2000-05-02 2004-10-26 Immusol, Inc. Cellular regulators of infectious agents and methods of use
US20020028465A1 (en) * 2000-05-03 2002-03-07 John Bertin Novel molecules of the NBS/LRR protein family and uses thereof
US7034135B2 (en) 2000-05-03 2006-04-25 Millennium Pharmaceuticals, Inc. Molecules of the NBS/LRR protein family and uses thereof
WO2001085921A2 (en) * 2000-05-12 2001-11-15 Merck Patent Gmbh Human serine-threonine kinase-4
US20020132298A1 (en) * 2000-11-14 2002-09-19 Millennium Pharmaceuticals, Inc. 67118, 67067, and 62092, human proteins and methods of use thereof
AU2001268060A1 (en) * 2000-05-15 2001-11-26 Curagen Corporation G-protein coupled receptor proteins and nucleic acids encoding same
AU2001263312A1 (en) * 2000-05-19 2001-12-03 Millennium Pharmaceuticals, Inc. 32244, a novel human amp-binding enzyme and uses thereof
WO2001090179A2 (en) * 2000-05-23 2001-11-29 Lexicon Genetics Incorporated Novel human thrombospondin-like proteins and polynucleotides encoding the same
GB2380197A (en) * 2000-05-26 2003-04-02 Aeomica Inc Myosin-like gene expressed in human heart and muscle
EP1158049A1 (en) * 2000-05-26 2001-11-28 Aeomica, INC. Myosin-like gene expressed in human heart and muscle
WO2001092524A2 (en) * 2000-05-26 2001-12-06 Aeomica, Inc. Myosin-like gene expressed in human heart and muscle
EP1700867A3 (en) * 2000-06-02 2006-09-20 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001262734B2 (en) * 2000-06-14 2004-09-30 Sankyo Company, Limited Ceramide kinase and DNA encoding the same
WO2001096561A1 (en) * 2000-06-16 2001-12-20 Merck Patent Gmbh Hunc-2, human member of unc-protein family
EP1176200A3 (en) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases or wound healing and their use in indentifying pharmacologically acitve substances
CN1281749C (en) 2000-06-26 2006-10-25 味之素株式会社 Polypeptides, use thereof and process for producing the same
AU2001270215A1 (en) * 2000-06-27 2002-01-08 Curagen Corporation Novel polynucleotides and polypeptides encoded thereby
EP1320590A2 (en) * 2000-07-13 2003-06-25 Millennium Pharmaceuticals, Inc. 47885, a novel human ubiquitin-activating enzyme and uses therefor
EP1174502A1 (en) * 2000-07-18 2002-01-23 Schering Corporation Type 2 dendritic cell precursor derived coding nucleic acids and related compositions and methods
US6740751B2 (en) 2000-07-18 2004-05-25 Board Of Regents, The University Of Texas System Methods and compositions for stabilizing microtubules and intermediate filaments in striated muscle cells
WO2002010217A2 (en) * 2000-08-02 2002-02-07 The Johns Hopkins University Endothelial cell expression patterns
CA2419810A1 (en) * 2000-08-18 2002-02-28 Merck Patent Gesellschaft Mit Beschraenkter Haftung Mfq-111, a novel human gtpase like protein
EP1311665A2 (en) * 2000-08-24 2003-05-21 Incyte Genomics, Inc. Kidney-specific protein
AU2001293778A1 (en) * 2000-08-28 2002-03-13 Lion Bioscience Ag Novel cofactors of the pregnane x receptor and methods of use
WO2002018582A2 (en) * 2000-08-31 2002-03-07 Millennium Pharmaceuticals, Inc. 62112, a novel human dehydrogenase and uses thereof
WO2002024739A2 (en) * 2000-09-21 2002-03-28 The Regents Of The University Of California Spas-1 cancer antigen
CA2423108A1 (en) * 2000-09-22 2003-03-19 Kyowa Hakko Kogyo Co., Ltd. .beta.-catenin nuclear localizing protein
WO2002024744A2 (en) * 2000-09-25 2002-03-28 Millennium Pharmaceuticals, Inc. 49938, a human phospholipid transporter and uses therefor
EP1370655A2 (en) * 2000-09-29 2003-12-17 Incyte Genomics, Inc. Secreted human proteins
US20020150916A1 (en) * 2000-10-05 2002-10-17 Rachel Meyers 43716, a novel human G-protein and uses thereof
DK1325130T3 (en) 2000-10-06 2010-05-25 Univ Yale Nogo Receptor Homologs
AU1313802A (en) 2000-10-12 2002-04-22 Ferring Bv Novel serine protease genes related to dppiv
AU2002221676A1 (en) * 2000-10-16 2002-04-29 Bayer Aktiengesellschaft Regulation of human acyl-coa dehydrogenase
US20020119518A1 (en) * 2000-10-17 2002-08-29 Merkulov Gennady V. Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU2001295778A1 (en) * 2000-10-20 2002-04-29 Inpharmatica Limited Novel cysteine proteases and uses thereof
JP2004512045A (en) * 2000-10-24 2004-04-22 アベンティス・ファーマ・ソシエテ・アノニム Nucleic acids that regulate the ABCA7 gene, molecules that modulate its activity, and therapeutic uses
FR2822165B1 (en) * 2000-10-24 2004-12-24 Aventis Pharma Sa NUCLEIC ACID REGULATING THE ABCA7 GENE, MOLECULES MODULATING ITS ACTIVITY AND THERAPEUTIC APPLICATIONS
AUPR107800A0 (en) * 2000-10-27 2000-11-23 University Of Sydney, The Peptide and nucleic acid molecule ii
IL155244A0 (en) * 2000-10-30 2003-11-23 Bristol Myers Squibb Co Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme
WO2002036781A2 (en) * 2000-10-31 2002-05-10 Bayer Aktiengesellschaft Regulation of human glutathione-s-transferase
US20030032776A1 (en) * 2000-11-02 2003-02-13 Feder John N. Polynucleotide encoding a novel human potassium channel beta-subunit, K+Mbeta1
US20040053835A1 (en) * 2000-11-17 2004-03-18 Sophia Kossida Regulation of human nmda receptor
AU2002228612A1 (en) 2000-11-22 2002-06-03 Bristol-Myers Squibb Company Cloning and expression of human slap-2: a novel sh2/sh3 domain-containing human slap homologue having immune cell-specific expression
CA2324663A1 (en) * 2000-11-27 2002-05-27 The Hospital For Sick Children A novel adapter gene
WO2002044358A2 (en) * 2000-11-28 2002-06-06 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosis and treatment of cancer using arginine m ethyltransferase 3
AU2002235748A1 (en) * 2000-12-05 2002-06-18 Bayer Aktiengesellschaft Regulation of human patched-like protein
AU2001297765A1 (en) * 2000-12-05 2002-10-21 Incyte Genomics, Inc. Ligases
AU2002222108A1 (en) * 2000-12-08 2002-06-18 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease
US20040082051A1 (en) * 2000-12-14 2004-04-29 Zhimin Zhu Regulation of human uridine kinase
US7122345B2 (en) 2001-01-09 2006-10-17 Curagen Corporation Nucleic acid encoding a NOVX13 polypeptide
EP1350847A4 (en) * 2001-01-09 2005-12-28 Inst Of Gene And Brain Science Human glioma antigen and process for preparing the same
WO2002055707A2 (en) * 2001-01-10 2002-07-18 Rigel Pharmaceuticals Inc Cloning of an inhibitor of antigen-receptor signaling by a retroviral-based functional screen
US6605710B2 (en) * 2001-01-11 2003-08-12 Board Of Trustees Of Michigan State University Gene whose expression promotes differentiation of myeloid progenitor cells into neutrophils and/or monocytes/macrophages
US20020119523A1 (en) * 2001-01-17 2002-08-29 Millennium Pharmaceuticals, Inc. 67073, a human phospholipid transporter family member and uses therefor
JPWO2002057444A1 (en) * 2001-01-22 2004-05-20 近藤　科江 Human apoptosis-related gene and its product, human apoptosis-related protein
EP1432801A2 (en) * 2001-02-06 2004-06-30 Incyte Genomics, Inc. Receptors and membrane-associated proteins
US20040132035A1 (en) * 2001-02-07 2004-07-08 Daemen Matthias Joseph A P Markers of unstable atherosclerotic plaques
AU2002247702A1 (en) * 2001-02-09 2002-08-28 Lion Bioscience Ag Novel cofactors of the estrogen receptor beta and methods of use
AU2002250911A1 (en) * 2001-02-12 2002-08-28 Bayer Aktiengesellschaft Isolated polynucleotides encoding putative tyrosine kinase
WO2002064777A2 (en) * 2001-02-14 2002-08-22 Axaron Bioscience Ag Proteins 7b6 and 11b4 and dna sequences encoding the same
GB0104440D0 (en) * 2001-02-22 2001-04-11 Oxford Biomedica Ltd Novel genes
EP1373526A4 (en) * 2001-03-08 2006-01-25 Curagen Corp Therapeutic polypeptides, nucleic acids encoding same, and methodes of use
EP1365801A4 (en) * 2001-03-08 2004-10-13 Nuvelo Inc Methods and materials relating to fibulin-like polypeptides and polynucleotides
AU2002250143A1 (en) * 2001-03-16 2002-10-03 Eli Lilly And Company Lp mammalian proteins; related reagents
US20020168668A1 (en) * 2001-03-27 2002-11-14 Millennium Pharmaceuticals, Inc. 14691, a human glutamate receptor family member and uses therefor
US6913904B2 (en) * 2001-03-27 2005-07-05 Applera Corporation Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof
EP1390057A4 (en) * 2001-04-03 2005-10-12 Curagen Corp Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and method of use
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
EP2280030A3 (en) 2001-04-10 2011-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
EP1573022B1 (en) 2001-04-10 2011-06-08 Agensys, Inc. Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer
WO2002083706A1 (en) * 2001-04-16 2002-10-24 Lexicon Genetics Incorporated Nucleic acid encoding a human adenylosuccinate synthetase
JP5232350B2 (en) * 2001-04-17 2013-07-10 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー Repeat sequence of CA125 gene and its use for diagnostic and therapeutic intervention
US7309760B2 (en) * 2001-04-17 2007-12-18 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
WO2002085922A2 (en) * 2001-04-23 2002-10-31 Curagen Corporation Proteins and nucleic acids encoding same
US20050065333A1 (en) * 2001-04-27 2005-03-24 Arun Seth Breast cancer-associated genes and uses thereof
AUPR470101A0 (en) * 2001-05-02 2001-05-24 Murdoch Childrens Research Institute, The A molecular marker
US20030017159A1 (en) * 2001-05-02 2003-01-23 Jerome Ritz Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof
ATE479748T1 (en) * 2001-05-29 2010-09-15 Human Cell Systems Inc TESTICULAR CARNITINE TRANSPORTER AND ITS GENE
CA2446610A1 (en) * 2001-06-06 2002-12-12 Human Genome Sciences, Inc. 20 human secreted proteins
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
EG26529A (en) * 2001-06-11 2014-01-27 مونسانتو تكنولوجى ل ل سى Cotton event mon 15985 and compositions and methods for detection thereof
AU2002315229A1 (en) * 2001-06-19 2003-01-02 The Regents Of The University Of California Histone deacetylase and methods of use thereof
EP1402031A2 (en) * 2001-06-21 2004-03-31 Isis Innovation Limited Atopy
AT410945B (en) * 2001-06-27 2003-08-25 Burkhard Dr Jansen Diagnosis of multiple sclerosis or tumors, by detecting absence of wild-type stem cell factor-apoptosis response gene, or the derived protein, also new nucleic acids
US20030120040A1 (en) 2001-06-29 2003-06-26 Genentech, Inc. Secreted and Transmembrane polypeptides and nucleic acids encoding the same
JP2004533841A (en) * 2001-07-05 2004-11-11 ワイス Aggrecanase molecule
JP4702819B2 (en) 2001-08-01 2011-06-15 生化学工業株式会社 Chondroitin synthase
GB2399086A (en) * 2001-08-02 2004-09-08 Aeomica Inc Human zinc finger containing gene MDZ4
AU2002367997A1 (en) * 2001-08-15 2003-12-19 Centre National De La Recherche Scientifique (Cnrs) Sut-2 and sut-3 genes, proteins and assays for inhibitors of lymphocyte adhesion
CA2461094A1 (en) 2001-09-25 2003-04-03 Sony Corporation P300 histone acetylase inhibitor
DE10148037A1 (en) * 2001-09-28 2003-04-17 Aventis Behring Gmbh Use of the protease activating the blood coagulation factor VII for the prophylaxis and therapy of vaso-proliferative diseases
WO2003031627A1 (en) * 2001-09-28 2003-04-17 Hokkaido Technology Licensing Office Co., Ltd. Platelet-origin polypeptides having sphingosine kinase activity and sphingosine kinase genes encoding the same
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
CA2463000A1 (en) * 2001-10-26 2003-08-07 Incyte Genomics, Inc. Vesicle-associated proteins
JPWO2003037930A1 (en) * 2001-10-29 2005-02-17 財団法人かずさディー・エヌ・エー研究所 Novel human N-methyl-D-aspartate (NMDA) glutamate receptor polypeptide and gene encoding the same
EP1512007A4 (en) * 2001-10-29 2005-08-17 Millennium Pharm Inc 32235, a human aminotransferase family member and uses therefor
GB2381526A (en) * 2001-11-03 2003-05-07 Sequenom Inc Detection of predisposition to osteoporosis
ATE553120T1 (en) 2001-11-16 2012-04-15 Eisai R&D Man Co Ltd PROTEINS OF THE JEAP FAMILY, COMPONENTS OF THE TIGHT CONNECTIONS OF THE EXOCRINE GLANDS
EP2014674B1 (en) 2001-11-26 2014-02-12 Laboratoire Biodim Protein-protein interactions in human immunodeficiency virus
AUPR913901A0 (en) * 2001-11-27 2001-12-20 Children's Medical Research Institute Muscle transcription factors
AU2002365894A1 (en) * 2001-11-30 2003-06-17 Children's Hospital Medical Center Antibodies to magmas and uses thereof
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
ES2337989T3 (en) * 2001-12-18 2010-05-03 Endocube Sas NEW PROTEINS ASSOCIATED WITH THE DEATH OF THE THAP FAMILY AND RELATED PAR4 ROUTES INVOLVED IN THE CONTROL OF APOPTOSIS.
WO2003064654A1 (en) * 2002-02-01 2003-08-07 Bayer Healthcare Ag Human serine/threonine protein kinase
JP2003252801A (en) * 2002-02-27 2003-09-10 Japan Science & Technology Corp Method for using pituitary-specific gene
US7993863B2 (en) 2002-03-19 2011-08-09 Children's Medical Center Corporation Methods for diagnosis and prognosis of cancer
WO2003083049A2 (en) 2002-03-22 2003-10-09 Munin Corporation Cloning and characterization of g+c-rich promoter binding protein
US7473526B2 (en) * 2002-03-29 2009-01-06 Veridex, Llc Breast cancer prognostic portfolio
WO2003102164A2 (en) * 2002-05-30 2003-12-11 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
WO2004000313A2 (en) * 2002-06-24 2003-12-31 Exonhit Therapeutics Sa Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds
GB0215406D0 (en) * 2002-07-03 2002-08-14 Inpharmatica Ltd Protein
US7115402B2 (en) 2002-07-09 2006-10-03 Bristol-Myers Squibb Company Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, BGS42
US7122358B2 (en) 2002-07-09 2006-10-17 Bristol-Myers Squibb Company Testis-specific tubulin tyrosine-ligase-like protein, BGS42
JP4508872B2 (en) 2002-07-25 2010-07-21 ソニー株式会社 Gene transcription regulator
WO2004012817A2 (en) * 2002-07-31 2004-02-12 Kylix B.V. Use of genes identified to be involved in tumor development for the development of anti-cancer drugs
DE10309368A1 (en) * 2002-08-06 2004-02-26 Aventis Behring Gmbh Intellectual Property/Legal Pharmaceutical preparation with RNA as a cofactor of hemostasis
EP1534833A4 (en) 2002-08-09 2006-06-07 Melbourne Health Mammalian grainyhead transcription factors
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
CA2497337A1 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Novel composition and methods for the treatment of psoriasis
WO2004031731A2 (en) * 2002-10-02 2004-04-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for controlling proliferation of cells
WO2004037858A2 (en) * 2002-10-25 2004-05-06 Technische Universitaet Muenchen Nipa, a nuclear interacting partner of anaplastic lymphoma kinase, polypeptides and use thereof
JP2006516189A (en) * 2002-11-15 2006-06-29 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー CA125 gene and its use for diagnosis and therapy
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
US20070009888A1 (en) * 2002-12-05 2007-01-11 Macina Roberto A Compositions, splice variants and methods relating to breast specific genes and proteins
GB0228337D0 (en) 2002-12-05 2003-01-08 Yorkshire Cancer Res Campaign Replication protein
WO2004063223A2 (en) * 2002-12-27 2004-07-29 Applied Research Systems Ars Holding N.V. Notch-like polypeptides
WO2004070025A2 (en) * 2003-02-05 2004-08-19 Juan Saus Novel goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
PL378582A1 (en) 2003-03-19 2006-05-02 Biogen Idec Ma Inc. Nogo receptor binding protein
ATE528397T1 (en) 2003-08-08 2011-10-15 Perseus Proteomics Inc GENE OVEREXPRESSED IN CANCER
WO2005023833A2 (en) * 2003-09-05 2005-03-17 Cellzome Ag Treatment of neurodegenerative diseases
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
BRPI0509420A (en) 2004-04-14 2007-09-04 Genentech Inc method of reducing or inhibiting angiogenesis and method of increasing efficacy of antiangiogenic agent treatment
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
CA2619256A1 (en) * 2004-09-24 2006-03-30 Mount Sinai Hospital Polynucleotides and polypeptides associated with trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover
GB0426960D0 (en) 2004-12-08 2005-01-12 Ares Trading Sa TGR-3 like protein receptor
CA2600749C (en) * 2005-03-10 2014-04-15 Nascacell Ip Gmbh Dimeric or multimeric microproteins
EP1904091A4 (en) 2005-07-07 2009-12-23 Univ Yale Compositions and methods for suppressing axonal growth inhibition
MX2008000253A (en) 2005-07-08 2008-04-02 Biogen Idec Inc Sp35 antibodies and uses thereof.
US7811787B2 (en) 2006-04-25 2010-10-12 Bristol-Myers Squibb Company Polynucleotides encoding human SLAP-2 variant, hSLAP-2v3
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
DE102008045696A1 (en) 2008-09-04 2010-03-11 Drk Blutspendedienst West Ggmbh Granulocyte HNA-3a / b antigen
JP5731986B2 (en) * 2008-12-09 2015-06-10 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Methods and compositions for specific modulation of MCL-1
CN102378766A (en) 2009-03-23 2012-03-14 夸克医药公司 Compounds compositions and methods of treating cancer and fibrotic diseases
CA2838400A1 (en) 2009-05-08 2010-11-11 Genentech, Inc. Humanized anti-egfl7 antibodies and methods using same
CN104470541A (en) 2012-05-14 2015-03-25 比奥根艾迪克Ma公司 Lingo-2 antagonists for treatment of conditions involving motor neurons
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN105073776B (en) 2012-11-13 2019-04-12 拜恩科技股份公司 For treating the preparation of the Cancerous disease of expression tight junction protein
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
EP3077411A1 (en) * 2013-12-03 2016-10-12 Institut National de la Santé et de la Recherche Médicale (INSERM) Mafb mutants and uses thereof
JP2018504400A (en) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． LINGO-1 antagonist and use for treatment of demyelinating disorders
CN112190710B (en) * 2020-10-28 2021-07-30 江苏省人民医院（南京医科大学第一附属医院） Application of lipid-derived polypeptide in preparation of metastatic breast cancer targeted drug
WO2022212928A1 (en) * 2021-04-02 2022-10-06 The Regents Of The University Of California Modified viruses and viral particles, methods of making, and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COLE S.T.: "Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.", NATURE, vol. 393, 11 June 1998 (1998-06-11), XP002144873 *
LAMERDIN J.E.: "Sequence analysis of a 3.5 Mb contig in human 19p13.3 containing a serine protease gene cluster.", EMEST DATABASE ENTRY, 8 February 1999 (1999-02-08), XP002144874 *
M.D. ADAMS ET AL.: "The genome sequence of Drosophila melanogaster.", SCIENCE, vol. 287, 24 March 2000 (2000-03-24), pages 2185 - 2195, XP002144875 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212228B2 (en) 2005-11-24 2015-12-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9499609B2 (en) 2005-11-24 2016-11-22 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9512232B2 (en) 2012-05-09 2016-12-06 Ganymed Pharmaceuticals Ag Antibodies against Claudin 18.2 useful in cancer diagnosis

Also Published As

Publication number Publication date
AU3774500A (en) 2000-10-16
CA2383592A1 (en) 2000-10-05
WO2000058473A2 (en) 2000-10-05
EP1165784A2 (en) 2002-01-02
JP2004507202A (en) 2004-03-11

Similar Documents

Publication Publication Date Title
WO2000058473A3 (en) Nucleic acids including open reading frames encoding polypeptides; 'orfx'
WO2001092523A3 (en) Human polynucleotides and polypeptides encoded thereby
WO2001007595A3 (en) Novel fibroblast growth factor and nucleic acids encoding same
WO2001036645A3 (en) Serine/threonine kinase and serine protease polypeptides and nucleic acids encoding same
WO2000053742A3 (en) Polynucleotides and proteins encoded thereby
WO2002066647A3 (en) Type 2 ctokine receptor and nucleic acids encoding same
WO2001049729A3 (en) Novex polypeptides, nucleic acids encoding same and their diagnostic and therapeutic use
WO2001074856A3 (en) Wnt-7b-like polypeptides and nucleic acids encoding same
WO2002002625A3 (en) Novel fibroblast growth factors and nucleic acids encoding same
WO2001070978A3 (en) Polypeptides and nucleic acids encoding same
WO2001062928A3 (en) Polypeptides and nucleic acids encoding same
WO2001044473A3 (en) Polypeptides and nucleic acids encoding same
WO2001061009A3 (en) Polypeptides and nucleic acids encoding same
WO2000078802A3 (en) Secreted polypeptides and corresponding polynucleotides
WO2001036638A8 (en) Polypeptides and nucleic acids encoding same
WO2003025147A3 (en) Novel polynucleotides and proteins encoded thereby
WO2000061754A3 (en) Human proteins and polynucleotides encoding them
WO2001023561A3 (en) Novel polynucleotides encoding proteins containing thrombospondin type 1 repeats
WO2000070046A3 (en) Secreted polypeptides and corresponding polynucleotides
WO2001085767A3 (en) Human proteins polynucleotides encoding them and methods of using the same
WO2001068851A3 (en) Polypeptides and nucleic acids encoding same
WO2001036635A3 (en) Neurite outgrowth-promoting factor homologue and nucleic acids encoding same
WO2003040345A3 (en) Type 2 cytokine receptor and nucleic acids encoding same
WO2001023572A3 (en) Polynucleotides and polypeptides encoded thereby
WO2001032874A3 (en) Polypeptides and nucleic acids encoding same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2383592

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 608754

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000916677

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 37745/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000916677

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000916677

Country of ref document: EP